Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 62 clinical trials
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.

  • 3 views
  • 23 Jan, 2021
MEK and Autophagy Inhibition in Metastatic/Locally Advanced Unresectable Neuroblastoma RAS (NRAS) Melanoma

pancreatic adenocarcinoma. The study team has shown in vivo, in four different NRAS mutated melanoma Patient Derived Xenograft (PDX) models that the combination of the MEK inhibitor trametinib and the

  • 0 views
  • 25 Jan, 2021
  • 5 locations
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

dabrafenib + trametinib with ipilimumab failed due to toxicity. Patients with elevated levels of serum LDH are less likely to respond to immunotherapy compared to patients with normal LDH levels

  • 5 views
  • 24 Jan, 2021
  • 13 locations
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Encorafenib Plus Binimetinib for People With BRAF V600E Mutated Relapsed/Refractory HCL

Background Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs might work better. Objective To test if …

  • 0 views
  • 20 Mar, 2021
  • 1 location
Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former

dabrafenib
trametinib
  • 87 views
  • 04 Jun, 2021
  • 13 locations
Pediatric Long-Term Follow-up and Rollover Study

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

trametinib
dabrafenib
  • 487 views
  • 28 Apr, 2021
  • 17 locations
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.

malignant melanoma of skin
KRAS
trametinib
combinations
BRAF
  • 272 views
  • 15 Jun, 2021
  • 35 locations
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with

  • 7 views
  • 14 May, 2021
  • 10 locations
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue

metastasis
tumor cells
measurable disease
carcinoma
cancer
  • 12 views
  • 26 Jan, 2021
  • 1 location